Biocon rallies 6%, hits record high on favourable ruling from US PTAB
Biocon's partner Mylan received a favourable ruling from U.S. Patent and Trademark Appeal Board (PTAB) on Sanofi's four device patents for Lantus SoloSTAR.
 "Biocon rallies 6%, hits record high on favourable ruling from US PTAB")
premium
Shares of Biocon rallied 6 per cent to hit a record high of Rs 377 on the BSE on Monday after its partner Mylan received a favourable ruling from US Patent and Trademark Appeal Board (PTAB) on Sanofi’s four device patents for Lantus SoloSTAR. The stock surpassed its previous high of Rs 368 touched on April 20, 2020.
“Te U.S. Patent and Trademark Appeal Board (PTAB) ruled in favour of Mylan, Biocon’s partner in inter-partes review (IPR) proceedings, finding all challenged claims of Sanofi’s Lantus SoloSTAR device patents unpatentable,” Biocon said in its press release.
The PTAB found three claims of patent unpatentable, and two claims to be patentable. However, Mylan and Biocon previously obtained a covenant not to sue from Sanofi on the patent and therefore this ruling does not impact Biocon and Mylan’s ability to commercialise Semglee (Insulin Glargine) upon final approval from the US Food and Drug Administration (USFDA), it added.
“The favourable ruling strengthens our resolve to provide high-quality, affordable Insulin Glargine to diabetic patients in the US and generate savings for their healthcare system. Our partner’s New Drug Application (NDA) for Semglee is under active review by the US FDA and this favourable ruling further clears the path for the anticipated launch of our Glargine in the U.S. in mid-CY20,” said Dr. Christiane Hamacher, CEO and Managing Director, Biocon Biologics.
Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes for the control of high blood sugar. Sanofi sells the product in vials (Lantus) and as a disposable injection pen (Lantus SoloSTAR).
Sanofi's total IQVIA sales for the 12 months ending 31 March 2020, were approximately $1.71 billion for Lantus 100 Units/mL and about $4.32 billion for Lantus SoloSTAR, it added.
“Te U.S. Patent and Trademark Appeal Board (PTAB) ruled in favour of Mylan, Biocon’s partner in inter-partes review (IPR) proceedings, finding all challenged claims of Sanofi’s Lantus SoloSTAR device patents unpatentable,” Biocon said in its press release.
The PTAB found three claims of patent unpatentable, and two claims to be patentable. However, Mylan and Biocon previously obtained a covenant not to sue from Sanofi on the patent and therefore this ruling does not impact Biocon and Mylan’s ability to commercialise Semglee (Insulin Glargine) upon final approval from the US Food and Drug Administration (USFDA), it added.
“The favourable ruling strengthens our resolve to provide high-quality, affordable Insulin Glargine to diabetic patients in the US and generate savings for their healthcare system. Our partner’s New Drug Application (NDA) for Semglee is under active review by the US FDA and this favourable ruling further clears the path for the anticipated launch of our Glargine in the U.S. in mid-CY20,” said Dr. Christiane Hamacher, CEO and Managing Director, Biocon Biologics.
Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes for the control of high blood sugar. Sanofi sells the product in vials (Lantus) and as a disposable injection pen (Lantus SoloSTAR).
Sanofi's total IQVIA sales for the 12 months ending 31 March 2020, were approximately $1.71 billion for Lantus 100 Units/mL and about $4.32 billion for Lantus SoloSTAR, it added.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%